S
Sling Therapeutics
Biotech & Life Sciences · Ann Arbor, United States · Founded 2020
A clinical-stage biopharmaceutical company developing an oral small molecule for the treatment of thyroid eye disease MoreLess
Sling Therapeutics is a biopharmaceutical company dedicated to the late-stage development of therapies for thyroid eye disease (TED). The company aims to improve the lives of patients and their families by focusing on high-quality clinical development and patient-centric approaches. Sling Therapeutics operates in the healthcare and pharmaceutical market, primarily serving patients, caregivers, and physicians dealing with thyroid eye disease. The company's business model revolves around the development and commercialization of its lead product, linsitinib, an oral therapy currently in Phase 2b clinical trials. Revenue is generated through the successful development, approval, and commercialization of this and potentially other therapies in their pipeline. Sling Therapeutics is driven by a team of experienced executives, drug developers, and scientific advisors who work with urgency and uphold the highest standards of quality.
Keywords: thyroid eye disease, biopharmaceutical, clinical development, patient-centric, linsitinib, Phase 2b trial, healthcare, pharmaceutical, oral therapy, high-quality standards.
Company overview
Sling Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2020
- Headquarters
- Ann Arbor, United States
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 39.9
Valuation & funding
Sling Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2022 | $35M | $140M | The Rise Fund (TPG) | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 12 |
| 2025 | 13 |
| 2024 | 7 |
| 2023 | 9 |
| 2022 | 6 |
Growth signals
Sling Therapeutics website traffic
Latest recorded traffic for Sling Therapeutics is 1.2K monthly website visits, down 14.3% over the last three months. Sling Therapeutics's team declined 7.7% over the past year.
Comparisons
Sling Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Sling Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
1 investor on Sling Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Sling Therapeutics has talent and traffic
team presence
In the news
Latest news about Sling Therapeutics
Recent press, funding announcements, and product moves mentioning Sling Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Sling Therapeutics
An AI-synthesized read of the highest-engagement posts about Sling Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sling Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.